SG10201404107SA - Antibodies Against Human TWEAK And Uses Thereof - Google Patents

Antibodies Against Human TWEAK And Uses Thereof

Info

Publication number
SG10201404107SA
SG10201404107SA SG10201404107SA SG10201404107SA SG10201404107SA SG 10201404107S A SG10201404107S A SG 10201404107SA SG 10201404107S A SG10201404107S A SG 10201404107SA SG 10201404107S A SG10201404107S A SG 10201404107SA SG 10201404107S A SG10201404107S A SG 10201404107SA
Authority
SG
Singapore
Prior art keywords
antibodies against
against human
human tweak
tweak
antibodies
Prior art date
Application number
SG10201404107SA
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201404107SA publication Critical patent/SG10201404107SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201404107SA 2009-04-02 2010-03-30 Antibodies Against Human TWEAK And Uses Thereof SG10201404107SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02

Publications (1)

Publication Number Publication Date
SG10201404107SA true SG10201404107SA (en) 2014-10-30

Family

ID=40673340

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011071487A SG175005A1 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof
SG10201404107SA SG10201404107SA (en) 2009-04-02 2010-03-30 Antibodies Against Human TWEAK And Uses Thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011071487A SG175005A1 (en) 2009-04-02 2010-03-30 Antibodies against human tweak and uses thereof

Country Status (23)

Country Link
US (3) US8093006B2 (fr)
EP (2) EP2414398A2 (fr)
JP (1) JP5596777B2 (fr)
KR (1) KR101344611B1 (fr)
CN (1) CN102369219A (fr)
AR (1) AR076020A1 (fr)
AU (1) AU2010233997A1 (fr)
BR (1) BRPI1014867A2 (fr)
CA (1) CA2756245A1 (fr)
CL (1) CL2011002452A1 (fr)
CO (1) CO6362025A2 (fr)
CR (1) CR20110462A (fr)
EC (1) ECSP11011362A (fr)
IL (1) IL214355A0 (fr)
MA (1) MA33097B1 (fr)
MX (1) MX2011010117A (fr)
NZ (1) NZ594347A (fr)
PE (1) PE20120577A1 (fr)
RU (1) RU2011143903A (fr)
SG (2) SG175005A1 (fr)
TW (1) TWI423815B (fr)
UA (1) UA105520C2 (fr)
WO (1) WO2010115555A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
CA2809632A1 (fr) 2010-10-05 2012-04-12 Monika Baehner Anticorps dirige contre le tweak humain et leurs utilisations
AU2012225246B2 (en) * 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CA2868404A1 (fr) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Anticorps bispecifiques diriges contre tweak humain et l'il17 humaine, et leurs utilisations
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
TW202035459A (zh) * 2018-10-31 2020-10-01 日商安斯泰來製藥股份有限公司 抗人類Fn14抗體

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CZ297387B6 (cs) 1996-08-07 2006-11-15 Biogen Idec Ma Inc. Sekvence DNA kódující ligand príbuzný TNF, polypeptid a zpusob jeho prípravy, protilátka reaktivní s polypeptidem a farmaceutická kompozice
WO1998035061A2 (fr) 1997-02-12 1998-08-13 Abbott Laboratories Element de la famille tnf utilise pour le traitement et le diagnostic d'une maladie
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
IL135051A0 (en) 1997-10-10 2001-05-20 Genentech Inc Apo-3 ligand polypeptide
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
WO2000052926A1 (fr) 1999-03-04 2000-09-08 Vision-Sciences Inc. Motif élémentaire de capteur d'image avec circuit de commande électronique réglable individuellement
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
WO2001030374A1 (fr) 1999-10-22 2001-05-03 The University Of Pittsburgh Proteines cellulaires ameliorant la prise de greffe de cellules souches et utilisations de ces proteines
ES2433011T3 (es) 1999-12-20 2013-12-05 Immunex Corporation Receptor TWEAK
JP2004500844A (ja) 2000-05-08 2004-01-15 バイオジェン　インコーポレイテッド Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
CA2587018A1 (fr) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
WO2006088890A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de l'accident vasculaire cerebral
WO2006089095A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de troubles neurologiques
EP1853312B1 (fr) 2005-03-07 2014-12-10 Genentech, Inc. Methodes et compositions de modulation de l'activite de tweak et de fn14
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
LT2460831T (lt) * 2005-05-27 2016-12-12 Biogen Ma Inc. Tweak rišantys antikūnai
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
US8852887B2 (en) 2014-10-07
PE20120577A1 (es) 2012-05-23
RU2011143903A (ru) 2013-05-10
CL2011002452A1 (es) 2012-03-23
US20120207750A1 (en) 2012-08-16
NZ594347A (en) 2012-09-28
US20100255008A1 (en) 2010-10-07
US20120083015A1 (en) 2012-04-05
UA105520C2 (uk) 2014-05-26
EP2597104A1 (fr) 2013-05-29
CN102369219A (zh) 2012-03-07
EP2414398A2 (fr) 2012-02-08
US8883976B2 (en) 2014-11-11
WO2010115555A3 (fr) 2011-01-06
MA33097B1 (fr) 2012-03-01
TWI423815B (zh) 2014-01-21
AU2010233997A1 (en) 2011-08-18
JP2012521771A (ja) 2012-09-20
CO6362025A2 (es) 2012-01-20
TW201039847A (en) 2010-11-16
WO2010115555A2 (fr) 2010-10-14
KR20110122868A (ko) 2011-11-11
BRPI1014867A2 (pt) 2016-04-12
US8093006B2 (en) 2012-01-10
MX2011010117A (es) 2011-10-14
ECSP11011362A (es) 2011-10-31
SG175005A1 (en) 2011-11-28
CR20110462A (es) 2011-09-21
AR076020A1 (es) 2011-05-11
IL214355A0 (en) 2011-09-27
CA2756245A1 (fr) 2010-10-14
JP5596777B2 (ja) 2014-09-24
KR101344611B1 (ko) 2013-12-30

Similar Documents

Publication Publication Date Title
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (fr) Anticorps anti-glp-1r et leurs utilisations
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
IL210804A (en) Benzylidenehydrazides and their uses
HK1186195A1 (zh) 抗人 的抗體及其用途
GB0914644D0 (en) Novel agents and uses thereof
IL214355A0 (en) Antibodies against human tweak and uses thereof
HK1195776A1 (zh) -α 抗-α 抗體及其應用
GB0807018D0 (en) Antibodies and treatment
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2402429A4 (fr) Bactérie produisant de l'équol et son utilisation
ZA201103456B (en) Leukolectins and uses thereof
EP2291377A4 (fr) Imidazopyrimidinones et leurs utilisations
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2247601A4 (fr) Thiazopyrimidinones et leurs utilisations
GB0903151D0 (en) Antibody uses and methods
HK1164193A1 (zh) 抗體及其用途
GB0912744D0 (en) Methods and uses
IL216440A0 (en) Antibodies against human ccn1 and uses thereof
GB0906115D0 (en) Antibody and uses thereof
GB0910620D0 (en) Agents and uses thereof
GB0920904D0 (en) Uses and methods
GB0902545D0 (en) Hygienic cake-cover and candle-holder